ANRO
NYSE · Pharmaceuticals
Alto Neuroscience Inc
$20.58
+0.39 (+1.93%)
Financial Highlights (FY 2025)
Revenue
112.34M
Net Income
25.21M
Gross Margin
45.6%
Profit Margin
22.4%
Rev Growth
+16.8%
D/E Ratio
0.26
Revenue & Net Income
Margin Trends
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Gross Margin | 45.6% | 45.6% | 45.6% |
| Operating Margin | 22.4% | 21.5% | 22.1% |
| Profit Margin | 22.4% | 19.9% | 20.8% |
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 112.34M | 107.15M | 117.41M |
| Gross Profit | 51.26M | 48.89M | 53.57M |
| Operating Income | 25.18M | 23.04M | 25.98M |
| Net Income | 25.21M | 21.35M | 24.46M |
| Gross Margin | 45.6% | 45.6% | 45.6% |
| Operating Margin | 22.4% | 21.5% | 22.1% |
| Profit Margin | 22.4% | 19.9% | 20.8% |
| Rev Growth | +16.8% | +14.3% | +23.4% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 67.91M | 61.60M | 64.44M |
| Total Equity | 266.22M | 240.58M | 244.12M |
| D/E Ratio | 0.26 | 0.26 | 0.26 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 29.11M | 29.85M | 33.13M |
| Free Cash Flow | 25.43M | 19.85M | 18.41M |